| Dr Jody W Houston, MD | |
|
505 S Nolen Dr, Southlake, TX 76092-9167 | |
| (817) 424-1525 | |
| (817) 424-3491 |
| Full Name | Dr Jody W Houston |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 25 Years |
| Location | 505 S Nolen Dr, Southlake, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891724100 | NPI | - | NPPES |
| 8V3623 | Other | TX | BCBSTX |
| M3589 | Other | TX | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | M3589 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Medical Center Grapevine | Grapevine, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Digestive Disease Consultants Pllc | 3375531379 | 544 |
News Archive
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding.
Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.
A Productivity Commission report, "Childhood Obesity: an Economic Perspective", released this Monday said that junk food taxes were not a cure for childhood obesity. It read, "Bans or taxes on particular energy-dense nutrient-poor foods, for example, face design difficulties, affect all consumers regardless of their weight status, and in the case of taxes, can have perverse budgetary and health effects particularly for the neediest groups."
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
To reduce an estimated half million deaths and two million hospitalizations from diarrhea caused by rotavirus each year, the WHO on Friday recommended that oral rotavirus vaccines be added to national childhood immunization programs, broadening access to the vaccine in the developing world, Reuters reports.
› Verified 2 days ago
| Entity Name | Texas Digestive Disease Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053397331 PECOS PAC ID: 3375531379 Enrollment ID: O20040505001844 |
News Archive
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding.
Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.
A Productivity Commission report, "Childhood Obesity: an Economic Perspective", released this Monday said that junk food taxes were not a cure for childhood obesity. It read, "Bans or taxes on particular energy-dense nutrient-poor foods, for example, face design difficulties, affect all consumers regardless of their weight status, and in the case of taxes, can have perverse budgetary and health effects particularly for the neediest groups."
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
To reduce an estimated half million deaths and two million hospitalizations from diarrhea caused by rotavirus each year, the WHO on Friday recommended that oral rotavirus vaccines be added to national childhood immunization programs, broadening access to the vaccine in the developing world, Reuters reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jody W Houston, MD Po Box 35629, Dallas, TX 75235-0629 Ph: (214) 424-2213 | Dr Jody W Houston, MD 505 S Nolen Dr, Southlake, TX 76092-9167 Ph: (817) 424-1525 |
News Archive
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding.
Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.
A Productivity Commission report, "Childhood Obesity: an Economic Perspective", released this Monday said that junk food taxes were not a cure for childhood obesity. It read, "Bans or taxes on particular energy-dense nutrient-poor foods, for example, face design difficulties, affect all consumers regardless of their weight status, and in the case of taxes, can have perverse budgetary and health effects particularly for the neediest groups."
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
To reduce an estimated half million deaths and two million hospitalizations from diarrhea caused by rotavirus each year, the WHO on Friday recommended that oral rotavirus vaccines be added to national childhood immunization programs, broadening access to the vaccine in the developing world, Reuters reports.
› Verified 2 days ago
Joseph Jasser, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 501 King Ranch Rd, Southlake, TX 76092 Phone: 916-851-2600 | |
Unknown Priyanka, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1207 S White Chapel Blvd Ste 275, Southlake, TX 76092 Phone: 682-416-9120 | |
Rina Sarkar, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 630 N Kimball Ave, Suite# 110, Southlake, TX 76092 Phone: 817-488-8080 | |
Dr. Sharmila Devidoss, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 701 Monte Carlo Dr, Southlake, TX 76092 Phone: 817-733-9367 | |
Raetasha Sheavette Dabney, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 431 E State Highway 114 Ste 470, Southlake, TX 76092 Phone: 214-379-2700 Fax: 972-869-3875 | |
Dr. Jeffrey A Smith, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 505 S Nolen Dr, Southlake, TX 76092 Phone: 817-424-1525 Fax: 817-424-3491 | |
Carl Edwin Ducharme, D.O. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 900 E Southlake Blvd Ste 200, Southlake, TX 76092 Phone: 817-310-6050 Fax: 817-310-6051 |